RT Journal Article
T1 Galectin-1: A Potential Biomarker Differentiating between Early Rheumatoid Arthritis and Spondyloarthritis
A1 Triguero-Martínez, Ana
A1 Roy-Vallejo, Emilia
A1 Gloria Tomero, Eva
A1 Montes, Nuria
A1 Fuente, Hortensia de la
A1 Ortiz, Ana María
A1 Castañeda, Santos
A1 Lamana Domínguez, Amalia
A1 González-Álvaro, Isidoro
AB Galectin-1 (Gal1) plays a regulatory role in the immune system. We have recently validated that Gal1 serum (sGal1) levels are increased in rheumatoid arthritis (RA) patients compared to healthy donors (HDs); however, there is no information on Gal1 in spondyloarthritis (SpA). Objective: To compare Gal1 levels in patients with SpA versus RA as a diagnostic biomarker. Methods: We studied sGal1 levels in HD (n = 52), SpA (n = 80) and RA patients (n = 64) who were randomly divided into discovery and validation sets. Synovial fluid (SF) from osteoarthritis (OA) (n = 28), peripheral SpA (n = 28) and RA (n = 28) were studied. In SpA patients, we analyzed the association between clinical parameters and sGal1 levels. Results: sGal1 levels were significantly lower in patients with SpA with respect to RA and similar to those of the HD. A cut-off of 20.50 ng/mL (sGal1) allowed one to differentiate RA patients from SpA and HD (Odd Ratio (OR) 8.23 and 12.64, respectively). Gal1 SF levels in SpA were slightly lower than OA patients and significantly lower than RA patients. No correlation was observed between sGal1 levels and clinical parameters in SpA patients. Conclusion: Gal1 could act as a diagnostic biomarker of RA and would allow one to distinguish SpA and RA patients.
PB MDPI
SN 2077-0383
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/94196
UL https://hdl.handle.net/20.500.14352/94196
LA eng
NO Triguero-Martínez, A.; Roy-Vallejo, E.; Tomero, E.G.; Montes, N.; Fuente, H.d.l.; Ortiz, A.M.; Castañeda, S.; Lamana, A.; González-Álvaro, I. Galectin-1: A Potential Biomarker Differentiating between Early Rheumatoid Arthritis and Spondyloarthritis. J. Clin. Med. 2022, 11, 6313. https://doi.org/10.3390/jcm11216313
NO This research was funded by grants RD21/0002/0027 and PI21/00526 to IG-A, PI21/01583 to H.dF and PI21/01474 to SC from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and co-funded by European regional development fund (ERDF) “A way to make Europe”. The work of ER-V is currently funded by a grant Rio-Hortega CM19/00149 from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and co-funded by European regional development fund (ERDF) “A way to make Europe”
NO Ministerio de Economía y Competitividad (España)
NO European Commission
DS Docta Complutense
RD 13 abr 2025